Eilean Therapeutics LLC, a US-based biopharmaceutical company, on Tuesday reported in vivo data for its first-in-class MALT1 degrader, TE205, as a disease-modifying therapy for ulcerative colitis at the 4th International Conference on Microbiology and Immunology in Las Vegas, Nevada.

In preclinical studies, TE205 demonstrated a robust and multifaceted immunomodulatory effect in the DSS-induced colitis model, achieving both structural and functional restoration of intestinal integrity. It effectively suppressed NF-kB signalling and pro-inflammatory cytokine production, rebalanced key T-cell and macrophage populations within the lamina propria, and restored epithelial barrier function and mucosal architecture. This was achieved by selectively degrading MALT1 (Mucosa-associated lymphoid tissue lymphoma translocation protein 1).

According to the company, these results establish TE205 as a potent, first-in-class MALT1 degrader with strong in vivo efficacy and clear disease-modifying potential for inflammatory bowel disease (IBD).